Profile data is unavailable for this security.
About the company
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
- Revenue in USD (TTM)752.00k
- Net income in USD-68.21m
- Incorporated2017
- Employees37.00
- LocationBioXcel Therapeutics Inc555 Long Wharf DrNEW HAVEN 06511-6107United StatesUSA
- Phone+1 (203) 643-8060
- Fax+1 (302) 636-5454
- Websitehttps://www.bioxceltherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyperion DeFi Inc | 345.32k | -26.40m | 25.50m | 13.00 | -- | 0.3047 | -- | 73.85 | -20.32 | -20.32 | 0.0385 | 9.88 | 0.0065 | -- | 1.06 | 26,563.08 | -48.31 | -102.28 | -59.47 | -168.53 | -798.11 | 60.58 | -7,385.51 | -856.97 | -- | -- | 0.0976 | -- | 1,412.93 | -- | -82.75 | -- | -0.6271 | -- |
| TherapeuticsMD Inc | 2.80m | 73.00k | 25.70m | 1.00 | 355.77 | 0.9362 | 55.86 | 9.19 | 0.0062 | 0.0261 | 0.2419 | 2.37 | 0.0715 | -- | 0.8002 | 2,796,000.00 | 0.1867 | -42.65 | 0.2169 | -112.14 | -- | -- | 2.61 | -193.47 | -- | -5,240.00 | 0.00 | -- | 35.25 | -48.72 | 69.97 | -- | -- | -- |
| Kyntra Bio Inc | 8.30m | -131.13m | 27.67m | 225.00 | -- | -- | -- | 3.33 | -32.49 | 53.34 | 2.05 | -4.21 | 0.0413 | -1.47 | 0.421 | 36,880.00 | -64.00 | -39.47 | -260.98 | -61.33 | 345.69 | 90.21 | -1,548.18 | -199.02 | 3.60 | -- | 0.5269 | -- | -36.71 | -35.07 | 52.60 | -- | -45.94 | -- |
| Aytu Biopharma Inc | 62.64m | -24.56m | 28.34m | 82.00 | -- | 2.00 | -- | 0.4524 | -3.40 | -3.39 | 5.63 | 1.32 | 0.5259 | 2.10 | 2.22 | 763,902.40 | -20.62 | -26.47 | -45.22 | -47.32 | 66.84 | 60.56 | -39.21 | -52.54 | 1.03 | 0.057 | 0.5958 | -- | 1.84 | 19.16 | -13.27 | -- | -- | -- |
| United-Guardian Inc | 10.06m | 1.96m | 30.28m | 24.00 | 15.45 | 2.86 | 14.67 | 3.01 | 0.4266 | 0.4266 | 2.19 | 2.30 | 0.7911 | 3.82 | 7.58 | 419,180.40 | 15.41 | 26.91 | 17.85 | 31.16 | 50.60 | 54.16 | 19.48 | 26.97 | 6.16 | -- | 0.00 | 92.34 | 11.91 | -2.18 | 25.94 | -7.35 | 30.65 | -8.64 |
| SCYNEXIS Inc | 2.93m | -25.30m | 31.55m | 28.00 | -- | 0.8659 | -- | 10.76 | -0.5107 | -0.5107 | 0.0593 | 0.8683 | 0.0391 | -- | 0.5776 | 104,714.30 | -33.71 | -20.51 | -43.65 | -24.97 | 33.32 | -- | -862.89 | -64.82 | -- | -- | 0.00 | -- | -97.33 | 98.68 | -131.75 | -- | -- | -- |
| Earth Science Tech Inc | 34.87m | 3.51m | 32.05m | 76.00 | 9.43 | 5.60 | 8.28 | 0.9191 | 0.0117 | 0.0117 | 0.1158 | 0.0196 | 5.06 | 14.89 | 148.30 | 458,876.60 | 50.52 | 24.04 | 76.21 | -- | 73.84 | 71.08 | 9.99 | 5.50 | 0.8606 | 5.65 | 0.0067 | -- | 177.05 | 128.98 | 300.63 | -- | -- | -- |
| Celularity Inc | 40.58m | -80.71m | 33.45m | 123.00 | -- | -- | -- | 0.8244 | -3.34 | -3.34 | 1.69 | -0.7121 | 0.3339 | 6.14 | 5.24 | 329,902.40 | -66.35 | -23.42 | -158.76 | -26.83 | 50.61 | -- | -198.75 | -294.70 | 0.123 | -6.57 | 2.01 | -- | 138.11 | -- | 70.51 | -- | -- | -- |
| BioXcel Therapeutics Inc | 752.00k | -68.21m | 34.99m | 37.00 | -- | -- | -- | 46.53 | -10.41 | -10.41 | 0.1023 | -4.45 | 0.016 | 0.9718 | 501.33 | 20,324.32 | -145.62 | -76.45 | -449.90 | -88.28 | -28.19 | -- | -9,070.61 | -14,760.23 | 1.16 | -3.25 | 5.40 | -- | 64.20 | -- | 66.71 | -- | -- | -- |
| Rockwell Medical Inc | 75.58m | -5.48m | 35.44m | 244.00 | -- | 0.9574 | -- | 0.4689 | -0.1583 | -0.1583 | 2.20 | 0.9395 | 1.32 | 12.92 | 8.78 | 309,741.80 | -9.63 | -32.92 | -12.15 | -46.61 | 15.81 | 8.00 | -7.30 | -23.86 | 3.50 | -6.13 | 0.2141 | -- | 21.38 | 10.61 | 94.31 | -- | 11.47 | -- |
| Zhengye Biotechnology Holding Ltd | 22.28m | -2.81m | 36.49m | 277.00 | -- | 0.8423 | 107.87 | 1.64 | -0.0591 | -0.0591 | 0.4793 | 0.9142 | 0.3099 | 1.62 | 2.04 | 80,439.45 | -4.60 | -- | -7.79 | -- | 37.37 | -- | -14.83 | -- | 1.10 | -7.00 | 0.1902 | -- | -11.95 | -- | -64.04 | -- | -- | -- |
| Medicus Pharma Ltd | -100.00bn | -100.00bn | 36.92m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0434 | -- | -- | -- | -- | -- | -361.95 | -- | -- | -- | -- | -- | -- | -- | -- | 1.13 | -- | -- | -- | -109.90 | -- | -- | -- |
| NovaBay Pharmaceuticals Inc | 2.83m | -7.95m | 38.66m | 14.00 | -- | -- | -- | 13.66 | -7.91 | 2.69 | 2.77 | 1.36 | 0.7686 | -- | 5.28 | 202,142.90 | -215.92 | -61.58 | -404.37 | -83.79 | 54.56 | 59.49 | -280.92 | -77.39 | -- | -91.56 | 0.0836 | -- | -33.58 | 8.19 | 48.52 | -- | -20.59 | -- |
| Healthy Extracts Inc | 3.59m | -1.17m | 39.65m | 2.00 | -- | 1.65 | -- | 11.05 | -0.3195 | -0.3195 | 0.9095 | 1.43 | 0.2505 | 1.42 | 140.67 | 1,794,555.00 | -8.19 | -61.21 | -9.09 | -111.60 | 52.37 | 51.30 | -32.71 | -82.01 | 0.6491 | -2.84 | 0.0421 | -- | 25.24 | 32.99 | 66.01 | -- | -- | -- |
| Talphera Inc | 28.00k | -12.46m | 41.73m | 13.00 | -- | 2.13 | -- | 1,490.51 | -0.3808 | -0.378 | 0.0009 | 0.4207 | 0.0011 | -- | -- | 2,153.85 | -48.15 | -14.86 | -54.44 | -19.40 | -- | -- | -44,503.57 | -446.19 | -- | -- | 0.00 | -- | -100.00 | -- | -26.41 | -- | -- | -- |
| BioScience Health Innovations Inc | 4.73m | 885.68k | 43.92m | -- | 206.50 | 25.67 | -- | 9.29 | 0.0194 | 0.0194 | 0.1313 | 0.1558 | 3.81 | 4.30 | 99.37 | -- | 71.34 | -- | 85.11 | -- | 63.64 | -- | 18.74 | -- | 3.47 | -- | 0.00 | -- | 208.73 | -- | 134.59 | -- | -- | -- |
Data as of Mar 03 2026. Currency figures normalised to BioXcel Therapeutics Inc's reporting currency: US Dollar USD
22.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 31 Dec 2025 | 1.84m | 12.61% |
| Oaktree Capital Management LPas of 31 Dec 2025 | 241.19k | 1.66% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 207.34k | 1.42% |
| Geode Capital Management LLCas of 31 Dec 2025 | 206.17k | 1.42% |
| Abante Asesores Gesti�n SGIIC SAas of 31 Dec 2025 | 196.29k | 1.35% |
| Edward D. Jones & Co. LP (Investment Management)as of 31 Dec 2025 | 137.69k | 0.95% |
| Jane Street Capital LLCas of 31 Dec 2025 | 127.50k | 0.88% |
| GSA Capital Partners LLPas of 31 Dec 2025 | 120.10k | 0.83% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 90.30k | 0.62% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 84.92k | 0.58% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
